EUVIMEDEUVIMED entdecken
Open Access

Engineered TCR-T cells secreting IFNα/anti-PD-L1 potentiate endogenous immunity to synergistically bolster the efficacy against solid tumors

Yuan Sun, Xuan Che, Xiya Wang, Pengchong Zhang, Lisha Ma, Xiaoyan Zhang, Jixiang Cao, Yun Bai

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2026.02.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Yuan Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms, Interferon-alpha, Receptors, Antigen, T-Cell. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key Technologies Research and Development Program, Major Research Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell receptor-engineered T cell (TCR-T) therapy represents a promising approach for treating solid tumors. However, its clinical efficacy remains suboptimal, primarily due to TCR-T dysfunction and insufficient endogenous immune activation within the tumor microenvironment. Here, we screen multiple cytokines and identify interferon α (IFNα) as a critical regulatory factor capable of improving the tumor microenvironment. However, systemic administration of IFNα leads to adverse effects and induces PD programmed cell death ligand 1 (PD-L1) upregulation on tumor cells. To overcome these challenges, we develop a TCR-T cell secreting IFNα/anti-PD-L1 to ensure treatment safety through dual tumor targeting via antigen-specific TCR and anti-PD-L1. Moreover, it effectively improves the tumor microenvironment and enhances TCR-T functionality by blocking PD-L1 and promoting Th1 differentiation of T cells, while simultaneously stimulating natural killer cell cytotoxicity and promoting dendritic cell maturation to mobilize endogenous immune cells. This synergistic approach enables the effective and safe eradication of solid tumors, offering a novel strategy to enhance the efficacy of TCR-T cell therapy with significant clinical translation potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsInterferon-alphaReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveAnimalsHumansMiceTumor MicroenvironmentCell Line, Tumor

Stichwörter der Autor:innen

TCR-T cell therapybispecific fusion proteinsendogenous immunityinterferon alphasolid tumors

Substanzen

B7-H1 AntigenInterferon-alphaReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing 100191, China.
  • Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing 100191, China. Electronic address: baiyun@bjmu.edu.cn.

Förderung

  • Key Technologies Research and Development Program
  • Major Research Plan

Zitieren

APA

Sun, Y., Che, X., Wang, X., Zhang, P., Ma, L., Zhang, X., Cao, J., & Bai, Y. (2026). Engineered TCR-T cells secreting IFNα/anti-PD-L1 potentiate endogenous immunity to synergistically bolster the efficacy against solid tumors. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.02.035

Vancouver

Sun Y, Che X, Wang X, Zhang P, Ma L, Zhang X, et al. Engineered TCR-T cells secreting IFNα/anti-PD-L1 potentiate endogenous immunity to synergistically bolster the efficacy against solid tumors. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.02.035

BibTeX
@article{Sun2026,
  author = {Sun, Yuan and Che, Xuan and Wang, Xiya and Zhang, Pengchong and Ma, Lisha and Zhang, Xiaoyan and Cao, Jixiang and Bai, Yun},
  title = {Engineered TCR-T cells secreting IFNα/anti-PD-L1 potentiate endogenous immunity to synergistically bolster the efficacy against solid tumors},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2026.02.035}
}
Kostenlos starten →